Paula Rother
Psychiatric/Mental Health · Norman, OKNPI 1780184754
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 576 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,741, 2.1 times the $1,299 reported in 2021. Among psychiatric/mental health clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 576 payments — averaging $15.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- AbbVie$1K
- Johnson & Johnson$1K
- Teva Pharmaceuticals USA, Inc.$872
- Otsuka America Pharmaceutical, Inc.$744
- Takeda Pharmaceuticals U.S.A., Inc.$587
- plus $3K from 19 others
What the payments were for
- Food & beverage$9,02799%
- Education$491%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 148 | $1,852 |
| AbbVie | 80 | $1,306 |
| Johnson & Johnson | 76 | $1,144 |
| Teva Pharmaceuticals USA, Inc. | 56 | $872 |
| Otsuka America Pharmaceutical, Inc. | 43 | $744 |
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $587 |
| Alkermes, Inc. | 26 | $472 |
| Supernus Pharmaceuticals, Inc. | 12 | $354 |
| Axsome Therapeutics, Inc. | 11 | $269 |
| Corium, LLC | 13 | $248 |
| E.r. Squibb & Sons, L.L.C. | 7 | $240 |
| Sunovion Pharmaceuticals Inc. | 35 | $202 |
| Neurocrine Biosciences, Inc. | 11 | $199 |
| Idorsia Pharmaceuticals US Inc | 7 | $174 |
| Lundbeck LLC | 6 | $125 |
| Vanda Pharmaceuticals Inc. | 4 | $97 |
| Almatica Pharma LLC | 2 | $44 |
| Noven Therapeutics, LLC | 2 | $30 |
| Collegium Pharmaceutical, Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $22 |
| Neos Therapeutics, LP | 1 | $22 |
| Eisai Inc. | 1 | $16 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
| Adlon Therapeutics L.p. | 1 | $12 |
| Sumitomo Pharma America, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$229
- CAPLYTA$211
- QELBREE$140
- INVEGA SUSTENNA$119
- COBENFY$118
How this compares
$9,076 in reported general payments places this provider in the 90th percentile of 231 psychiatric/mental health providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxepin Hcl | 13 | $509 |
| Duloxetine Hcl | 17 | $355 |
| Buspirone Hcl | 12 | $254 |
| Bupropion XlBupropion Hcl | 13 | $156 |
| Clonazepam | 13 | $133 |
| Fluoxetine Hcl | 11 | $41 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Norman
- Amy BoggsNorman$15K
- Nicole HolzerNorman$12K
- Laura HallNorman$10K
- Melissa BelangerNorman$10K
- Teresa ShermanNorman$8K
- Vallie CopleyNorman$6K
- Renate WinninghamNorman$6K
- Enieni OkoyaNorman$5K
- Craig PattonNorman$3K
- Meryl AaronEdmond$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.